Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Acq. announced

Forian Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 4 WYGOD MARTIN J (Director) has filed a Form 4 on Forian Inc.
Txns: Bought 1,700 shares @ $2.38, valued at $4k
08/23/2023 4 Kassam-Adams Shahir (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 788 shares @ $2.5, valued at $2k
Granted 956 shares @ $2.5, valued at $2.4k
08/21/2023 4 Kassam-Adams Shahir (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 31,993 shares @ $2.5, valued at $80k
Granted 448 shares @ $2.5, valued at $1.1k
Granted 5,502 shares @ $2.5, valued at $13.8k
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 4 Wygod Max C (Exec Chairman, CEO & President) has filed a Form 4 on Forian Inc.
Txns: Granted 19 shares @ $2.57, valued at $48.8
Granted 206 shares @ $2.54, valued at $523.2
Granted 800 shares @ $2.57, valued at $2.1k
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Newtown, PA, August 10, 2023 – via NewMediaWire – Forian Inc. , a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended June 30, 2023. “Forian’s commitment to delivering value to our customers and shareholders in a more challenging fiscal environment is evident from another quarter of operational and financial achievements. We continued to realize the benefits of our business streamlining, cost rationalization and operating leverage to reduce our cash burn while showing positive Adjusted EBITDA and keeping pace to meet our year-end revenue guidance,” stated Max Wygod, Chairman and Chief Executive Officer of Forian. Second Quarter 2023 Financial Results ● Forian delivered the fo..."
07/27/2023 8-K Completion of Acquisition or Disposition of Assets  Interactive Data
06/01/2023 4 WYGOD MARTIN J (Director) has filed a Form 4 on Forian Inc.
Txns: Bought 4,565 shares @ $2.39, valued at $10.9k
Bought 4,789 shares @ $2.4, valued at $11.5k
05/25/2023 4 WYGOD MARTIN J (Director) has filed a Form 4 on Forian Inc.
Txns: Bought 5,999 shares @ $2.38, valued at $14.3k
Bought 1,327 shares @ $2.35, valued at $3.1k
Bought 3,000 shares @ $2.34, valued at $7k
05/22/2023 4 WYGOD MARTIN J (Director) has filed a Form 4 on Forian Inc.
Txns: Bought 5,444 shares @ $2.29, valued at $12.5k
05/18/2023 4 TROTMAN STANLEY S JR (Director) has filed a Form 4 on Forian Inc.
Txns: Bought 7,657 shares @ $2.4, valued at $18.4k
Bought 12,343 shares @ $2.4, valued at $29.6k
05/12/2023 8-K Quarterly results
Docs: "Newtown, PA, May 12, 2023 – via NewMediaWire – Forian Inc. , a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended March 31, 2023. “As we continue our transition into a pure-play healthcare information company, Forian delivered another quarter of strong operational and financial performance,” stated Max Wygod, Chairman and Chief Executive Officer of Forian. Discontinued Operations As disclosed in its filings with the United States Securities and Exchange Commission , Forian completed the disposition of its cannabis software business on February 10, 2023. Through this transaction, and the previous dispositions in 2022 of Forian’s web design and security monitoring businesses, Forian..."
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 8-K Quarterly results
03/24/2023 4 Kassam-Adams Shahir (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 15,000 options to buy @ $3.14, valued at $47.1k
03/24/2023 4 Vuori Kristiina MD (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 15,000 options to buy @ $3.14, valued at $47.1k
03/24/2023 4 TROTMAN STANLEY S JR (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 15,000 options to buy @ $3.14, valued at $47.1k
03/24/2023 4/A Spaniel Edward Francis Jr (EVP, Gen Counsel & Secretary) has filed a Form 4 on Forian Inc.
Txns: Paid exercise price by delivering 7,885 shares @ $4.38, valued at $34.5k
03/24/2023 4 BANWELL IAN (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 15,000 options to buy @ $3.14, valued at $47.1k
03/24/2023 4 Hajj Jennifer (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 15,000 options to buy @ $3.14, valued at $47.1k
03/24/2023 4 ADLER MARK J MD (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 15,000 options to buy @ $3.14, valued at $47.1k
03/24/2023 4 Varadhan Alyssa F (Director) has filed a Form 4 on Forian Inc.
Txns: Granted 15,000 options to buy @ $3.14, valued at $47.1k
03/07/2023 4 Spaniel Edward Francis Jr (EVP, Gen Counsel & Secretary) has filed a Form 4 on Forian Inc.
Txns: Paid exercise price by delivering 9,226 shares @ $4.38, valued at $40.4k
02/13/2023 8-K Quarterly results
02/09/2023 SC 13G/A FEINBERG LARRY N reports a 5.4% stake in FORIAN INC.
11/18/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
Docs: "Newtown, PA / August 11, 2022 / Forian Inc. , a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for the quarter ended June 30, 2022. “Forian delivered strong financial results in the second quarter, reflecting growing demand across our offerings,” said Max Wygod, Forian Executive Chairman. “The second quarter passed an inflection point in the business where we now see our growth directly driving towards substantial profitability.” Forian Chief Executive Officer Dan Barton continued, “Second quarter 2022 financial results built upon our momentum of strong sales of our subscription-based healthcare information offerings coupled with execution on cost management strategies.” Second Quarter 2022 Financial R..."
06/21/2022 8-K Quarterly results
05/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy